Clinical trials: Sitagliptin, completed
Type 2 Diabetes Mellitus
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
- Trial name
- NCT00541775
- Testing
- Sitagliptin, Comparator: Rosiglitazone, Comparator: Metformin
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
The goal of this clinical trial is to compare the effects of Sitagliptin and Empagliflozin in combination with metformin on High sensitivity C reactive proteins (hs-CRP) levels and efficacy in T2DM patients.
- Trial name
- NCT06952231
- Testing
- Sitagliptin + Metformin, Empagliflozin + Metformin
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- University of Lahore
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of…
- Trial name
- NCT00842556
- Testing
- Dapagliflozin, Glimepiride, Sitagliptin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Osteoporosis, Bone Loss, Postmenopausal
DPP4-Inhibitors and Bone Metabolism in Diabetes
Background Bone frailty and fractures are common conditions in patients with type 2 diabetes (T2D) and represent a major cause of morbidity and hospitalization in this population.
- Conditions
- Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2
- Trial name
- SlowDOWN (NCT06770894)
- Testing
- Sitagliptin 100 mg
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Azienda Policlinico Umberto I
Bioequivalence, Type 2 Diabetes
Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers
The objective of this study was to determine the bioequivalence of two different formulations of sitagliptin/ metformin after a single oral dose administration under fed conditions.
- Trial name
- NCT05549583
- Testing
- Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Chronic Kidney Disease
Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04882813
- Testing
- Dapagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 87,727 people
- Sponsor
- Brigham and Women's Hospital
Diabetes
Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose levels and preserves pancreatic beta cell function in patients with type 2 diabetes.
- Trial name
- NCT01100125
- Testing
- sitagliptin, insulin dose increase
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes
A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)
This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin…
- Trial name
- NCT01034111
- Testing
- Sitagliptin phosphate, Metformin
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in…
- Trial name
- NCT02284893
- Testing
- Saxagliptin, Dapagliflozin, Sitagliptin
- Where
- 79 sites in United States, Hungary and 4 more
- Volunteers
- 461 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
START-J: SiTAgliptin in eldeRly Trial in Japan
The purpose of this study is to compare the efficacy and the safety of sitagliptin and glimepiride in drug naïve elderly patients with Type 2 diabetes as evaluated by HbA1c change from baseline at 52 W as efficacy and incidence…
- Trial name
- START-J (NCT01183104)
- Testing
- Sitagliptin, Glimepiride
- Where
- Japan
- Volunteers
- 305 people
- Sponsor
- Japan Association for Diabetes Education and Care
Diabetes, Type 2
Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes
Type 2 diabetic patients who fast during Ramadan experience swings in glycaemic control between hypoglycaemic troughs and hyperglycaemic spikes.
- Trial name
- NCT01624116
- Testing
- Acarbose, Diet and lifestyle, Metformin
- Where
- Pakistan
- Volunteers
- 161 people
- Sponsor
- Services Hospital, Lahore
Psoriasis
Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)
The primary purpose of this study is to determine if sitagliptin (Januvia®) improves psoriasis severity after 24 weeks of treatment in 60 participants with psoriasis who do not have type 2 diabetes mellitus, and who are due to…
- Trial name
- DINUP (NCT02347501)
- Testing
- Sitagliptin (Januvia)
- Where
- Ireland
- Volunteers
- 118 people
- Sponsor
- University College Dublin
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily…
- Trial name
- NCT01582308
- Testing
- Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on…
- Trial name
- NCT02099110
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 1,233 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.
- Trial name
- NCT01376323
- Testing
- GSK256073 1mg, GSK256073 5mg, GSK256073 10mg
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Treatment of Diabetes After Gastric Bypass With Sitagliptin
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
- Trial name
- LAF33 (NCT01512797)
- Testing
- Sitagliptin phosphate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Blandine Laferrere
Hyperglycemia
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is…
- Trial name
- SITA-CABGDM (NCT02556918)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 3 sites in United States
- Volunteers
- 202 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT02647320
- Testing
- Sitagliptin 100 mg, DS-8500a 25mg
- Where
- 58 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Daiichi Sankyo